header logo
Vallibel FD
vallible LE
Latest
Three Ebola vaccines in development amid growing outbreak fears
Three Ebola vaccines in development amid growing outbreak fears
Mobitel inner 1278

Three new vaccines are being developed to tackle the rare species of Ebola that has already killed nearly 250 people.

 

The International Aids Vaccine Initiative (IAVI), which is working on one vaccine, said the outbreak was threatening to be the worst ever.

 

The University of Oxford and the pharma company Moderna are also researching vaccines against the Bundibugyo species.

 

The Coalition for Epidemic Preparedness Innovations, which is providing funding to each group, said "every day counts".

 

There are now more than 1,000 suspected cases in the DR Congo with nine confirmed cases in neighbouring Uganda.

 

There is growing concern this outbreak – which was detected only after it had spread in a conflict zone with limited healthcare resources – could reach the size of the largest ever Ebola outbreak in West Africa in 2014-16. Then, nearly 29,000 people were infected and more than 11,000 died.

 

Dr Mark Feinberg, head of IAVI, said: “I think this is clearly threatening to be as severe an outbreak as that, if not even worse, and development of a vaccine, and other countermeasures, is clearly a priority.”

 

It echoes concerns from the medical charity Médecins Sans Frontières (MSF) which said the situation was "deeply alarming" and never before had "so many cases" been recorded so soon.

 

Vaccines must be developed for each individual species of Ebola – there are six, but only three are known to cause outbreaks.

 

There is a vaccine for the most common Zaire species, but this outbreak is being caused by another species, called Bundibugyo. It has only been seen twice before and there is no approved vaccine.

 

IAVI is working on a modified version of the Zaire Ebola vaccine to fight Bundibugyo. The experimental jab has been tested in monkeys where it rapidly trained the immune system and gave close to 100% protection.

 

Feinberg said their evidence so far meant he was "optimistic about the potential", but currently it would take seven to nine months to get the vaccine ready for clinical trials - although they are trying to "accelerate those timelines".

 

Meanwhile, the pharmaceutical company Moderna has announced it is using its mRNA technology – which was deployed to rapidly develop vaccines in the Covid pandemic – to work on Bundibugyo.

 

"We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most," said Stéphane Bancel, chief executive officer of Moderna.

 

And the University of Oxford has already said it is working on its own vaccine technology, which also saved lives in Covid, to develop a fresh Ebola vaccine.

 

This should be ready for clinical trials in two to three months.

 

Each vaccine aims to train the body to spot the same structure on the surface of the virus – known as the Bundibugyo glycoprotein. However, each uses a different technology to get there.

 

IAVI uses a live, but harmless virus that has been engineered so it also has the Ebola glycoprotein. The immune system fights off the harmless virus and learns to fight Ebola in the process.

 

The mRNA vaccine and the Oxford vaccine both deliver a snippet of genetic code into the body. Once inside it orders the construction of the Bundibugyo glycoprotein, which the body recognises as foreign and starts to attack.

 

All would mean that the immune system has a head start when it comes to fighting a real Ebola infection.

 

However, differences in the technologies and the way they train the immune system could affect levels of protection or the number of doses needed. All this needs to be tested in clinical trials.

 

The Coalition for Epidemic Preparedness Innovations (Cepi) is funding the early stages of research.

 

"With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease," said Dr Richard Hatchett, CEO of CEPI.

 

Dr Tedros Adhanom Ghebreyesus, the director general of the World Health Organization, said: “A Bundibugyo vaccine could help to control this epidemic and strengthen preparedness for future outbreaks.”

 

Source: BBC

– Agencies

Disclaimer: All the comments will be moderated by the AD editorial. Abstain from posting comments that are obscene, defamatory or slanderous. Please avoid outside hyperlinks inside the comment and avoid typing all capitalized comments. Help us delete comments that do not follow these guidelines by flagging them (mouse over a comment and click the flag icon on the right side). Do use these forums to voice your opinions and create healthy discourse.

Comments

0
Comments are disabled

Note: Due to legal constraints, the Ada Derana Editorial team has taken a decision to disable comments on all articles concerning ongoing court procedures.

MostRead
Mobitel 1278
VideoStories
Two company directors arrested and remanded  for allegedly defrauding 2,000 individuals of Rs. 4 bln

Two company directors arrested and remanded for allegedly defrauding 2,000 individuals of Rs. 4 bln

Opposition Leader calls for stronger protection of the  fundamental rights of children, women &youth

Opposition Leader calls for stronger protection of the fundamental rights of children, women &youth

Dilith Jayaweera-led Sarvajana Balaya delegation  in Japan for GLEC summit

Dilith Jayaweera-led Sarvajana Balaya delegation in Japan for GLEC summit

Earth-sized planets open new avenues 	 in search for life – NASA scientist Dr. Sarath Gunapala

Earth-sized planets open new avenues in search for life – NASA scientist Dr. Sarath Gunapala

Top UN court finds Myanmar committed genocide  against Muslim Rohingya

Top UN court finds Myanmar committed genocide against Muslim Rohingya

Headline inflation expected to reach 9%  by month-end - CBSL Governor

Headline inflation expected to reach 9% by month-end - CBSL Governor

China a close and dependable friend  of Sri Lanka, says Minister Anil Jayantha

China a close and dependable friend of Sri Lanka, says Minister Anil Jayantha

Can satellite data help improve disaster response? Senior Research Scientist at NASA explains

Can satellite data help improve disaster response? Senior Research Scientist at NASA explains

Bitumen shortage disrupts road development projects in Sri Lanka; RDA seeks alternative supplies

Bitumen shortage disrupts road development projects in Sri Lanka; RDA seeks alternative supplies

Minister urges govt workers engaged in trade union action to submit proposals to Salaries Commission

Minister urges govt workers engaged in trade union action to submit proposals to Salaries Commission

 Experts warn of significant rise in antibiotic resistance 40,000 non-physicians prescribing drugs?

Experts warn of significant rise in antibiotic resistance 40,000 non-physicians prescribing drugs?

Rajangane Saddharathana remanded over violent clashes in A’pura,  three other suspects granted bail

Rajangane Saddharathana remanded over violent clashes in A’pura, three other suspects granted bail

Appeals Court upholds four-year prison sentence  imposed on Ven. Gnanasara Thero

Appeals Court upholds four-year prison sentence imposed on Ven. Gnanasara Thero

Court suspends bail granted to Namal Rajapaksa Shashi Weerawansa’s two-year prison sentence upheld

Court suspends bail granted to Namal Rajapaksa Shashi Weerawansa’s two-year prison sentence upheld

 “I exposed corruption and not wronged” Trade union activist Ananda Palitha remanded until Nov. 25

“I exposed corruption and not wronged” Trade union activist Ananda Palitha remanded until Nov. 25

Lassana Flora